Hikari Power Ltd Invests $632,000 in Zoetis Inc. $ZTS

Hikari Power Ltd bought a new stake in Zoetis Inc. (NYSE:ZTS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 8,790 shares of the company’s stock, valued at approximately $632,000. Zoetis comprises approximately 0.1% of Hikari Power Ltd’s portfolio, making the stock its 27th largest position.

Several other institutional investors also recently bought and sold shares of ZTS. Louisiana State Employees Retirement System bought a new stake in Zoetis in the 1st quarter worth $2,542,000. Deutsche Bank AG raised its stake in shares of Zoetis by 19.1% during the fourth quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after acquiring an additional 891,921 shares during the last quarter. Pincus Capital Management LP bought a new position in shares of Zoetis during the fourth quarter valued at about $2,109,000. Highbridge Capital Management LLC purchased a new stake in shares of Zoetis during the fourth quarter worth about $7,004,000. Finally, Pacer Advisors Inc. grew its stake in shares of Zoetis by 16.7% in the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock worth $19,572,000 after purchasing an additional 23,687 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $73.64 on Monday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a one year low of $71.45 and a one year high of $160.48. The company has a 50-day simple moving average of $76.30 and a two-hundred day simple moving average of $98.84. The firm has a market capitalization of $30.43 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.28 and a beta of 0.73.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the firm posted $1.76 EPS. The business’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.19 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 34.93%.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZTS shares. JPMorgan Chase & Co. reduced their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. HSBC cut their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Stifel Nicolaus reduced their target price on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. UBS Group dropped their price target on Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Finally, Citigroup cut their price target on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus price target of $109.62.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.